Testing effectiveness (Phase 2)WithdrawnNCT03739606
What this trial is testing
Flotetuzumab in Treating Patients With Recurrent or Refractory CD123 Positive Blood Cancer
Who this might be right for
Acute Biphenotypic LeukemiaAcute LeukemiaChronic Myelogenous Leukemia, BCR-ABL1 Positive+12 more
City of Hope Medical Center